Arax Advisory Partners’s Kiniksa Pharmaceuticals KNSA Stock Holding History

Arax Advisory Partners’s Portfolio KNSA Stock Details KNSA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$963	Buy	20 +17	+567%	+$753	﹤0.01%	3307
2025 Q4	$124	Sell	3 -4,006	-100%	-$161K	﹤0.01%	3794
2025 Q3	$156K	Buy	+4,009	New	+$130K	﹤0.01%	1357
2025 Q1	–	Sell	-1	Closed	-$20	–	2882
2024 Q4	$20	Hold	1	–	–	﹤0.01%	2407
2024 Q3	$25	Hold	1	–	–	﹤0.01%	2600
2024 Q2	$19	Buy	+1	New	+$19	﹤0.01%	2527

Other funds holding KNSA

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

RCMNY

Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Arrowstreet Capital Boston, Massachusetts $185B AUM 39.58% 1-Year Est. Return

Arax Advisory Partners's KNSA Position: Q1 2026 in Review

Arax Advisory Partners increased its Kiniksa Pharmaceuticals (KNSA) stake by 567% in Q1 2026, buying an estimated $753 and bringing the position to 20 shares worth $963. The position accounts for ﹤0.01% of the portfolio, ranked #3307.

Arax Advisory Partners first reported a position in KNSA in Q2 2024 and has held it in 6 quarters since. The position peaked at $156K in Q3 2025. 228 funds tracked by Wall St. Rank hold KNSA as of Q1 2026.

Arax Advisory Partners held 20 shares of Kiniksa Pharmaceuticals worth $963 as of Q1 2026.
Arax Advisory Partners bought 17 Kiniksa Pharmaceuticals shares in Q1 2026, an estimated $753.
Kiniksa Pharmaceuticals made up ﹤0.01% of Arax Advisory Partners's portfolio in Q1 2026, its #3307 holding.
Arax Advisory Partners first reported a position in Kiniksa Pharmaceuticals in Q2 2024 and has held it in 6 quarters since.
Arax Advisory Partners's Kiniksa Pharmaceuticals position peaked at $156K in Q3 2025.
228 funds tracked by Wall St. Rank held Kiniksa Pharmaceuticals as of Q1 2026.

Based on Arax Advisory Partners's 13F filing for Q1 2026, filed 13 May 2026.